NFE2L2 and Parkinson disease: In Parkinson’s disease, for instance, epigenetic silencing of NRF2, e.g., via lncRNA MALAT1, has been shown to enhance inflammasome activation and progressive neuronal loss, further illustrating the sensitivity of NRF2-BDNF signaling to chromatin-level dysregulation [78].